SAN DIEGO, Feb. 4 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. , a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company’s President and CEO Theodore Schroeder will present the company’s corporate overview on Tuesday, February 10, 2009 at 9:00am Eastern Time (6:00am Pacific Time) during the BIO CEO and Investor Conference at the Waldorf Astoria Hotel in New York City.
The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals’ website at www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 30 days.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence’s pipeline, visit www.cadencepharm.com.
Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.
CONTACT: Anna Gralinska, Director, Investor Relations of Cadence
Pharmaceuticals, Inc., +1-858-436-1452
Web site: http://www.cadencepharm.com/
